Astellas Pharma has initiated a global campaign to address the critical issue of delayed bladder cancer diagnoses. In collaboration with the World Bladder Cancer Patient Coalition (WBCPC) and behavioral scientists, the company aims to understand the barriers preventing individuals from seeking timely medical attention for bladder cancer symptoms.
Bladder cancer often goes undetected until advanced stages, significantly reducing survival rates. By exploring cultural, emotional, and societal factors influencing patient behavior, Astellas seeks to develop strategies that encourage earlier diagnosis and improve outcomes for those affected by this disease.
This initiative underscores Astellas’ commitment to patient-centric approaches and aligns with the broader efforts within the Leiden Bio Science Park to enhance healthcare through innovative research and collaboration.
Read more here
Researchers at Leiden University Medical Center (LUMC) have mapped the mechanism of action of a promising new antibiotic. Under a cryo-electron microscope, researchers Mia Urem...
Leiden, November 12 - The project “Omics in the Polder” from Leiden University of Applied Sciences has been nominated for the RAAK Award. This award is presented annually to the...
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...